KNSA
Kiniksa Pharmaceuticals International, plc
$61.69
-0.29 (-0.47%)
At close · Jul 15
Market Cap
$9.33B
Shares
153,876,032
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$677.56M
+60.1%
FY2025
Net Income
$59.01M
+236.6%
FY2025
Gross Margin
88.54%
+2.9pp
FY2025
Operating Margin
11.4%
+22.2pp
FY2025
Diluted EPS
$0.75
+225%
FY2025
Operating Cash Flow
$137.99M
+437.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| $930M – $945M | $754.05M | $677.56M | $423.24M | $270.26M | $220.18M | $38.54M | — | — | — | — | |
| — | $80.6M | $77.67M | $60.91M | $33.41M | $22.9M | $9.1M | — | — | — | — | |
| — | $673.44M | $599.89M | $362.33M | $236.85M | $197.29M | $29.44M | — | — | — | — | |
| — | — | 88.54% | 85.61% | 87.64% | 89.6% | 76.39% | — | — | — | — | |
| — | $105M | $96.85M | $111.62M | $76.1M | $65.49M | $99.3M | $112.04M | $135M | $86.6M | $56.36M | |
| — | $57.44M | — | — | — | — | — | $45.32M | $34.96M | $21.56M | $9.04M | |
| — | $213.89M | $196.27M | $168.01M | $129.43M | $97.95M | $85.95M | $45.32M | $34.96M | — | — | |
| — | — | $1.55M | $1.7M | $2.34M | $2.4M | $2.36M | $2.41M | $2.07M | — | — | |
| — | $177.26M | — | — | — | — | — | $157.36M | $169.96M | $108.16M | $65.4M | |
| — | $93.22M | $77.22M | -$45.62M | -$25.2M | $9.77M | -$156.64M | -$157.36M | -$169.96M | -$108.16M | -$65.4M | |
| — | — | 11.4% | -10.78% | -9.32% | 4.44% | -406.38% | — | — | — | — | |
| — | — | $78.78M | -$43.92M | -$22.86M | $12.18M | -$154.28M | -$154.96M | -$167.9M | — | — | |
| — | — | $11.64M | $9.04M | $8.23M | $1.23M | $97K | $1.13M | $6.05M | $4.72M | $529K | |
| — | $105.98M | $88.87M | -$36.15M | -$16.65M | $11.03M | -$156.54M | -$156.23M | -$163.91M | -$103.44M | -$64.87M | |
| — | $32.93M | $29.86M | $7.04M | -$30.74M | -$172.34M | $1.39M | $5.15M | -$2.05M | -$214K | $2000 | |
| — | $73.06M | $59.01M | -$43.19M | $14.08M | $183.36M | -$157.92M | -$161.38M | -$161.87M | -$103.23M | -$64.87M | |
| — | — | 8.71% | -10.21% | 5.21% | 83.28% | -409.72% | — | — | — | — | |
| — | $72.56M | $59.14M | -$43.36M | $14.05M | $183.47M | -$157.96M | -$161.45M | -$161.83M | -$103.23M | -$64.87M | |
| USD/shares | — | — | $0.80 | -$0.60 | $0.20 | $2.64 | -$2.30 | -$2.61 | -$2.99 | — | — |
| USD/shares | — | — | $0.75 | -$0.60 | $0.20 | $2.60 | -$2.30 | -$2.61 | -$2.99 | — | — |
| shares | — | — | 74.2M | 71.42M | 70.06M | 69.38M | 68.58M | 61.84M | 54.05M | 29.55M | 1.81M |
| shares | — | — | 78.98M | 71.42M | 71.92M | 70.42M | 68.58M | 61.84M | 54.05M | 29.55M | 1.81M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2017–FY2018: $0 in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.14×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.02×
P/E (TTM)
66.64×
Drug Manufacturers - Specialty & Generic median 20.19×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Pharmaceutical Segment | $677,564,000 | $423,239,000 | $270,259,000 |
By Product & Service (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Product | $677,564,000 | $417,029,000 | $233,176,000 | $122,524,000 | $38,544,000 |
| Collaboration | — | $6,210,000 | $37,083,000 | $97,656,000 | — |
Key facts
CIK
1730430
CUSIP
G52694109
13F (30d)
13 filings
12 filers
Visit website
Investor relations